Best Places to Work 2009: Industry - Top Large Companies

Rank Company Name # R&D Employees R&D New Hires in 2008 Net income (billions) Significant Developments
1 Pioneer Hi-Bred 2,200 359 $4 (gross revenue) Pioneer reached $4 billion in revenue for the first time in 2008.
2 Monsanto 3,700 500+ $2.02 Completed North American regulatory submissions for the first-ever biotech drought-tolerant corn.
3 Amgen 7,850 * $4.20 Received regulatory approval in the United States and Australia for Nplate, a drug that stimulates platelet production for patients with chronic immune thrombocytopenic purpura.
4 DuPont 5,000 250+ $30.40 Commercialized 901 new products and applications in 2008, bringing the total to more than 5,000 new products and applications launched in the past five years.
5 Johnson & Johnson * * $63.7 (net sales) Licensed several new molecular entities, including Doribax for pneumonia, Intelence for HIV, and NUCYNTA for pain.
6 Abbott Laboratories 8,000 500+ $5.20 Nine major new product approvals, including the leading drug-eluting stent XIENCE V, and new indications for the biologic therapy HUMIRA.
7 Novartis 13,000 378 $8.20 Has three medicines under priority review by the US Food and Drug Administration--Affinitor for advanced kidney cancer, Gleevec/Glivec as adjuvant therapy in GIST, and Coartem for malaria.
8 Schering Plough * * $18.50 Successfully integrated Organon programs, and in the European Union launched BRIDION, a novel anesthetic agent.
9 EMD Serono 318 318 4.987 euros Announced planned expansion of its research facility in Billerica, Mass., focusing on oncology and neurodegenerative diseases.
10 AstraZeneca 12,000 972 $31.60 Has two new product submissions for motavizumab, an improved antirespiratory syncytial virus monoclonal antibody, and Onglyza(tm), for treating Type 2 diabetes.

Best Places to Work 2009: Industry - Top Small Companies

Rank Company Name # R&D Employees R&D New Hires in 2008 Significant Developments
1 Infinity Pharmaceuticals 126 27 Continuing Phase 3 registration trial in the lead product candidate, IPI-504 and multiple Phase 2 trials, and two candidates in early clinical trials.
2 GeneDx 12 5 Became the first company to offer clinical diagnostic testing using Next Generation sequencing technology for discovering causative mutations in patients with hypertrophic cardiomyopathy.
3 Wyatt Technology 18 2 Remained profitable, added staff, and brought out an all-new Dynamic Light scattering instrument, the DynaPro NanoStar.
4 Vertex Pharmaceuticals 723 111 Received clinical results showing that the HCV protease inhibitor, known as telaprevir, has the potential to cure more than 50 percent of patients who failed prior HCV treatment.
5 Millennium: The Takeda Oncology Company 600 114 Initiated several clinical trials ahead of schedule and doubled its oncology pipeline to 14 molecules as a result of the company's acquisition by Takeda.
6 Alnylam 137 48 Established human proof of concept with an RNAi therapeutic, advanced its pipeline with ALN-RSV and ALN-VSP clinical programs, and formed four major alliances.
7 DynPort Vaccine 65 12 Received a $32 million award to establish a Phase 1 clinical trial unit for infectious disease and continued developing vaccines for botulinum neurotoxin, plague, and tularemia.
8 Integrated DNA Technologies 41 3 Opened a production facility in Leuven, Belgium, launched PrimeTime™ qPCR Assays, and opened a clinical and commercial manufacturing unit in Coralville, Iowa.
9 Tengion 72 15 Completed Phase 2 human clinical trial in the United States with the Tengion Neo-Bladder Augment™ for children with neurogenic bladder due to spina bifida.
10 Transform Pharmaceuticals 63 0 Modified its mission to focus on developing innovative drug/device combination products for Johnson & Johnson.
* Company declined to provide information